Shroom Chocolate Bars and Gummies: What Is In Them

Not medical advice. Harm reduction information for people who have already decided to use. In an emergency, call your local emergency number. Some links are affiliate links; we may earn a commission at no cost to you.

Contents

What the lab testing actually found
Two more datasets, same story
Diamond Shruumz, and why an unknown dose is the real risk
A recall does not clear the shelves
Can you check one yourself?
If you have one anyway
What the label is worth
Sources

The word “mushroom” on the package predicts almost nothing about what is inside. Three separate laboratory studies have bought these bars and gummies off retail shelves and analysed them, and they agree on that much. The dangerous failure mode is not that the product is a placebo. It is that it often contains a different drug, at a dose nobody disclosed, in a wrapper that looks professional.

What the lab testing actually found

The clearest dataset is a research letter published in JAMA Network Open in September 2025. Researchers at Oregon State University and Rose City Laboratories bought 12 products at Portland retail shops, 11 gummies and a chocolate, and ran them through accredited HPLC, then GC-MS and three separate high resolution LC-MS instruments.

Not one contained psilocybin. The gummy whose label promised 100 mg of psilocybin per piece contained no psilocybin and nothing else active either. The gummy listing muscarine and muscimol contained neither, and neither compound turned up in any of the 12.

What was in them instead:

Three products plus the chocolate contained psilocin but no psilocybin and none of its natural biosynthetic precursors (baeocystin, norbaeocystin). The authors read that pattern as adulteration with synthetic psilocin rather than mushroom material.
Two gummies contained synthetic tryptamines, specifically mipracetin (4-acetoxy-N-methyl-N-isopropyltryptamine), 4-hydroxy-diethyltryptamine, and isomers of each. These do not occur in Psilocybe mushrooms at all.
One gummy contained a kava extract (kavain, yangonin, dihydromethysticin, methysticin). Kava has been linked to liver injury, and nobody eating a “mushroom gummy” is watching for that.
One gummy contained a cannabis extract, including delta-9-THC, CBD, CBDV, CBC and CBN. None of it was on the label.
One contained caffeine. Four contained no active ingredient detectable by any of those methods.

Two more datasets, same story

A team from the Oregon Poison Center and UCSF bought 8 gummy products from 7 Portland smoke and vape shops and analysed them by LC-QToF-MS, publishing in Clinical Toxicology in April 2025. Seven of the 8 contained psilocin and 6 contained 4-acetoxy-DMT, a synthetic tryptamine metabolised to psilocin that does not occur in mushrooms. One product marketed as psilocybin-free tested positive for psilocybin, one marketed as a nootropic contained undisclosed delta-9-THC, and the two claiming Amanita muscaria extract contained neither ibotenic acid nor muscimol but did contain tryptamines.

A University of Mississippi group analysed 27 commercial products, 14 gummies, 3 chocolates, 6 capsules, a tablet and 3 powders, in the International Journal of Medicinal Mushrooms in 2025. Eleven did contain psilocin and psilocybin as expected, so not every product is a lie. But 5 contained none of the five target compounds, one labelled “no psilocybin” contained both, and in the gummies claiming Amanita extracts, muscimol and muscarine appeared without ibotenic acid.

Those three studies disagree with each other about the Amanita products, and the disagreement is itself the finding: no consistent manufacturing standard sits behind any of these labels, so results vary shop to shop. A public health report from Charlottesville, Virginia separately documented Schedule I substances in “nootropic” gummies sold as Amanita or other mushroom products during 2023 and 2024.

Diamond Shruumz, and why an unknown dose is the real risk

The CDC and FDA outbreak investigation into Diamond Shruumz microdosing chocolate bars, published in MMWR, counted 180 poisoning cases across 34 states between January and October 2024, with 73 hospitalisations, 38 intensive care admissions, 29 intubations and two deaths.

Against other mushroom-containing chocolate products, Diamond Shruumz bars carried higher odds of hospitalisation (OR 3.29), intensive care admission (OR 6.30), seizures (OR 8.45) and intubation (OR 8.04), and eating more predicted worse outcomes. Testing found muscimol, psilocin and kavalactones in some but not all products, which is precisely the inconsistency that makes dosing impossible.

Psilocybin from actual mushrooms has a wide physiological safety margin, which we cover in can you overdose on magic mushrooms. None of that reasoning transfers to a product whose active ingredient is unknown, unmeasured, and possibly a synthetic compound with no published human toxicology.

A recall does not clear the shelves

Researchers tracked Diamond Shruumz listings before and after the recall, publishing in the Journal of Medical Internet Research in June 2025. Beforehand they found 67 domains, 8 e-commerce shops and 49 social media posts actively selling. Afterwards, 45 of those 67 domains were still marketing it, and simulated test purchases succeeded on 15. Assume recalled stock is still circulating.

Can you check one yourself?

Honestly, not well, and we are not going to pretend otherwise to sell you something. Ehrlich turns purple in the presence of indoles, so it reacts to psilocin, 4-AcO-DMT and other tryptamines alike. Three problems follow from that.

It cannot tell them apart: purple means an indole is here, not psilocybin is here. It cannot count milligrams, and colour intensity is not dose, and dose is the entire problem with these products. And the matrix ruins it, because sugar, gelatin, cocoa butter and fat all interfere with colour development, which makes a gummy or a chocolate close to a worst case sample for a colour test.

A no-colour result on something sold as psilocybin is informative in one direction only: it suggests no indole is present. A reagent kit earns its place with powders and pills, and our Ehrlich reagent guide covers what those reactions do and do not distinguish. On an edible, treat it as a weak signal and never as a clearance.

If you have one anyway

Treat it as an unknown substance at an unknown dose, not as a mushroom.
Start with a small fraction of one piece, wait a full two hours, and do not redose on a slow come-up. Uneven mixing within a single bar means one square is not one dose.
Do not stack it with alcohol, other serotonergic drugs, or stimulants.
Have a sober person present who knows what you took and where the packaging is.
If someone has seizures, will not wake up, or is severely agitated with a fast heart rate, call emergency services. Bring the packaging. In the US, Poison Control is 1-800-222-1222.

What the label is worth

Across 47 products in three published analyses, the label was a poor guide to the contents in most cases. A professional wrapper, a QR code or a claimed lab result changes none of that, because no enforced standard sits behind any of it. An identified whole mushroom from a known source has a far more predictable composition than a manufactured edible, with the serious caveat that misidentification kills people, covered in psilocybin lookalikes and deadly Galerina.

For dosing, preparation and what to do when a trip goes badly, see our psilocybin harm reduction guide and how to stop a bad trip.

Sources